London · Delayed Price · Currency is GBP · Price in USD AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of GBP 196.16 billion. The enterprise value is 215.08 billion.
| Market Cap | 196.16B |
| Enterprise Value | 215.08B |
Important Dates
The next estimated earnings date is Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | Aug 8, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 32.40 and the forward PE ratio is 17.50.
| PE Ratio | 32.40 |
| Forward PE | 17.50 |
| PS Ratio | 4.76 |
| PB Ratio | 6.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 24.05 |
| P/OCF Ratio | 20.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.15, with an EV/FCF ratio of 26.37.
| EV / Earnings | 35.52 |
| EV / Sales | 5.22 |
| EV / EBITDA | 15.15 |
| EV / EBIT | 20.57 |
| EV / FCF | 26.37 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 0.74.
| Current Ratio | 0.86 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 2.95 |
| Interest Coverage | 10.77 |
Financial Efficiency
Return on equity (ROE) is 19.67% and return on invested capital (ROIC) is 11.88%.
| Return on Equity (ROE) | 19.67% |
| Return on Assets (ROA) | 8.28% |
| Return on Invested Capital (ROIC) | 11.88% |
| Return on Capital Employed (ROCE) | 18.19% |
| Revenue Per Employee | 437,329 |
| Profits Per Employee | 64,205 |
| Employee Count | 94,300 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, AstraZeneca has paid 1.26 billion in taxes.
| Income Tax | 1.26B |
| Effective Tax Rate | 17.17% |
Stock Price Statistics
The stock price has increased by +6.70% in the last 52 weeks. The beta is 0.18, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +6.70% |
| 50-Day Moving Average | 68.96 |
| 200-Day Moving Average | 75.22 |
| Relative Strength Index (RSI) | 65.17 |
| Average Volume (20 Days) | 6,939 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of GBP 41.24 billion and earned 6.05 billion in profits. Earnings per share was 3.87.
| Revenue | 41.24B |
| Gross Profit | 33.93B |
| Operating Income | 10.47B |
| Pretax Income | 7.32B |
| Net Income | 6.05B |
| EBITDA | 13.96B |
| EBIT | 10.47B |
| Earnings Per Share (EPS) | 3.87 |
Balance Sheet
The company has 5.19 billion in cash and 24.04 billion in debt, giving a net cash position of -18.85 billion.
| Cash & Cash Equivalents | 5.19B |
| Total Debt | 24.04B |
| Net Cash | -18.85B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 32.71B |
| Book Value Per Share | 21.06 |
| Working Capital | -3.36B |
Cash Flow
In the last 12 months, operating cash flow was 9.77 billion and capital expenditures -1.62 billion, giving a free cash flow of 8.16 billion.
| Operating Cash Flow | 9.77B |
| Capital Expenditures | -1.62B |
| Free Cash Flow | 8.16B |
| FCF Per Share | n/a |
Margins
Gross margin is 82.26%, with operating and profit margins of 25.40% and 14.68%.
| Gross Margin | 82.26% |
| Operating Margin | 25.40% |
| Pretax Margin | 17.74% |
| Profit Margin | 14.68% |
| EBITDA Margin | 33.85% |
| EBIT Margin | 25.40% |
| FCF Margin | 19.78% |
Dividends & Yields
This stock pays an annual dividend of 0.88, which amounts to a dividend yield of 1.05%.
| Dividend Per Share | 0.88 |
| Dividend Yield | 1.05% |
| Dividend Growth (YoY) | 3.74% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 22.79% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 1.13% |
| Earnings Yield | 3.09% |
| FCF Yield | 4.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 8, 1998. It was a forward split with a ratio of 3.
| Last Split Date | Apr 8, 1998 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 6 |